Vision-related quality of life in spondyloarthritis patients with a history of acute anterior uveitis under treatment with golimumab: 12 months results of the GO-VISION observational study



Acute anterior uveitis (AAU) is one of the most common extra-articular manifestations of spondyloarthritis (SpA), causing a significant burden on quality of life (QoL). The GO-EASY Study provided evidence that GLM decreases the AAU occurrence rate in SpA. We aim to study the impact of GLM on the change of vision-related (VR) QoL in subjects with SpA.


Prospective multicentre observational study of SpA patients with a history of AAU treated with GLM followed-up for 12 months. We intend to recruit 30 patients, and we report herein the outcomes for the first 10 patients enrolled. The occurrence of AAU was assessed in the 2 years before GLM treatment onset and the 12 months of follow-up. The risk for a new AAU was calculated for each period. VR QoL was assessed with the self-administered NEI VFQ-25 questionnaire. Adverse events were noted.


10 patients (50% female, 70% TNFi-naive, mean age 45.8±11.1 years [range 22-65]) have completed the 12 months of follow-up. The total number of AAU flares in the 2 years preceding the start of GLM was 10, a number reduced to 1 during the 12 months of treatment. The AAU incidence rate was reduced from 1.52 to 0.10 per 100 patient-years (incidence ratio-ratio 14.79 [2.39;610.52], p<0.01). At baseline, 24 weeks and 48 weeks after GLM onset, the mean overall index NEI VFQ-25 total score was 72.4±12.0, 84.6±17.2, and 89.4±8.6, respectively. The difference across the three measurements was assessed with generalized estimating equations and was <0.001. No significant or new adverse events occurred.


The GO-VISION study is the first prospective study in the uveitis setting designed to have a patient-reported outcome measure as the primary outcome. Data from the GO-VISION study suggests that GLM is safe and effective in patients with SpA and history of AAU, reducing the AAU occurrence rate and potentially increasing VR QoL. 

Previous slide
Next slide